Lena Cords

German Study Prize of the Körber Foundation Awarded to Lena Cords

Awards & Grants Environmental Health PRM

Dr. Lena Cords, a researcher at Helmholtz Munich, has been awarded the German Study Prize by the Körber Foundation in the category of natural and technical sciences for her doctoral thesis at the University of Zurich and ETH Zurich. The prize is endowed with 25,000 euros. In her work, she investigated the role of connective tissue in cancer.

When Connective Tissue Fights Cancer

While working with Prof. Bernd Bodenmiller's group at UZH and ETH Zurich, Dr. Lena Cords developed a novel classification system for cancer-associated fibroblasts (CAFs). These connective tissue cells constantly interact with tumor cells, significantly impacting tumor development by either supporting or suppressing its growth. Using her classification system, Lena Cords demonstrated that the distribution of different CAF types strongly influences both patient prognosis and therapy success.

The aim of her doctoral thesis was to identify possible new therapeutic approaches that focus not on the tumor itself but on the connective tissue surrounding the tumor. “Connective tissue therapy has the potential to become the next milestone in cancer treatment. A cancer-type-independent classification system for cancer-associated fibroblasts, like the one I developed in my research, can pave the way for this. With this system, we can predict which connective tissue cells should be specifically targeted. I see this as a crucial step toward precision medicine.” Since February 2024, Lena Cords has been conducting research in the Precision Regenerative Medicine Group led by Prof. Herbert Schiller at Helmholtz Munich, supported by an EMBO Postdoctoral Fellowship.

About the German Study Prize

The Körber Foundation awards one first prize of €25,000 and two second prizes of €5,000 in each of the three categories: Social Sciences, Natural and Technical Sciences, and Humanities and Cultural Studies. This year, 719 participants submitted entries. The Körber Foundation's German Study Prize is awarded annually to doctoral students who have addressed socially relevant topics in their dissertations and presented tangible results. The patron of the award is the President of the Bundestag, Bärbel Bas. The award ceremony will take place in Berlin in December 2024.

Lena Cords PostDoc PRM
Dr. Lena Cords

Postdoctoral Fellow

Related news

[Translate to German:] Pulmonary capillary network in human precision cut lung slices (hPCLS)

AI, New Research Findings, Environmental Health, PRM, LHI,

Therapien für Lungenkrankheiten schneller entwickeln: Neue Erkenntnisse aus der Einzelzellgenomik

Warum erkranken unsere Lungen und wie können wir mit Medikamenten gezielter an bestimmten Signalwegen der Zellen ansetzen? Um diese Fragen zu beantworten, sammeln Forschende um Prof. Herbert Schiller und Dr. Gerald Burgstaller von Helmholtz Munich…

Superimposed human FSP1 structure with its cofactors, FAD, NADH, and CoQ5

New Research Findings, Molecular Targets and Therapeutics, MCD,

Revolutionäre Ansätze in der Krebstherapie: neuer Wirkstoff zur Ferroptoseauslösung

Forschende um Dr. Marcus Conrad von Helmholtz Munich haben einen neuen Wirkstoff für die Krebstherapie namens viFSP1 entdeckt, der sowohl in menschlichen Krebszellen als auch in denen von Mäusen den Zelltod durch Ferroptose induziert. Ferroptose ist…

AI menschlicher Körper

Environmental Health, LHI, Computational Health, ICB,

Eine Reise in die Geheimnisse unserer Zellen

Was ist der Human Cell Atlas (HCA) und welche wichtige Rolle hat Helmholtz Munich?

HMGU_Icon_Environm_Health

Featured Publication,

Immuntherapie: Antikörper-Bausatz gegen Tumore

DNA-Origami-Strukturen mit Antikörpern, die das Immunsystem gezielt gegen Tumorzellen richten

Immuntherapien gelten im Kampf gegen Krebs als besonders vielversprechend. Das Prinzip: Das körpereigene Immunsystem so aktivieren, dass es schädliche…

The X-ray of the human brain closeup image

Transfer, Awards & Grants, SAT,

Gehirntumore im Visier: Neuer Wirkstoffkandidat in klinischer Studie

Klinische Studien sind ein Meilenstein in der Entwicklung sicherer und wirksamer Medikamente und Therapien. Ein von Helmholtz Munich entwickelter Antikörper startet jetzt in eine klinische Phase-1-Studie. Gemeinsam mit dem Unternehmen ITM Isotope…